Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Q1 FY27 Earnings Presentation
18 slides from Rhythm Biosciences's earnings presentation, Nov 4, 2026
Slide 1: Rhythm Biosciences Q1 FY27 Update
rsonal use only Rhythm Biosciences An ASX Life Sciences Growth Opportunity Q1 FY27 UPDATE: 4TH NOVEMBER 2026 ASX: RHY
Slide 2: Disclaimer
Disclaimer rsonal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, represent
Slide 3: Detecting cancer earlier to save lives
Detecting cancer earlier to save lives rsonal use only Rhythm Biosciences is an ASX-listed company building a precision diagnostics platform focused on earlier cancer detection, risk assessment and improved patient outcomes. Non-invasive blood-based bowel cancer detection test Assessing cancer risk
Slide 4: Cancer is often detected too late
Cancer is often detected too late Earlier detection significantly improves survival outcomes and lowers treatment costs. rsonal use only 15,500+ new colorectal cancer cases diagnosed every year in Australia >50% diagnosed as late-stage disease (Stages III or IV) 10% 5-year survival rate when diagnos
Slide 5: Detecting cancer earlier saves lives
Detecting cancer earlier saves lives Two complementary platforms. One longitudinal precision cancer diagnostic strategy. rsonal use only RISK ASSESSMENT DISEASE DETECTION Who is at risk? Who has the disease? Genomic cancer risk assessment that identifies Blood-based bowel cancer detection that impro
Slide 6: Blood-based colorectal cancer detection platform (ColoSTAT)
rsonal use only A blood-based colorectal cancer detection platform designed to aid effective early diagnosis. www.colostat.com Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY) www.rhythmbio.com
Slide 7: Million patients waiting on a colonoscopy decision
22 million patients waiting on a colonoscopy decision… 22M symptomatic patients could benefit from better- informed colonoscopy decisions. That’s approximately rsonal use only 40% of annual colonoscopy volumes worldwide. Estimated annual triage An alternative to stool-based testing opportunity by re
Slide 8: Scaling ColoSTAT through established clinical channels
Scaling ColoSTAT® through established clinical channels Clinically validated. Partner-enabled. Built for national scale. rsonal use only AN ESTABLISHED MARKET A NATIONAL REFERRAL BASE EVIDENCE-LED ADOPTION >800,000 ~41,000 Clinical and colonoscopies performed primary care and specialist economic ann
Slide 9: How we grow revenue
How we grow revenue Four ColoSTAT® growth levers that multiply each other – all already in motion rsonal use only LEVER 1 LEVER 2 LEVER 3 LEVER 4 More doctors More collection Medicare International ordering sites reimbursement markets Making ColoSTAT® easy to More places close to home for A Medicare
Slide 10: ColoSTAT demand is building
ColoSTAT® demand is building Q1 FY27: more tests, more repeat doctors, easier access TEST VOLUMES REPEAT ORDERING PATIENT ACCESS EASIER ORDERING rsonal use only +56% ~20% 100+ Live growth in ColoSTAT® tests of requesting doctors are 4Cyte collection sites across in MedicalDirector since on Q4 FY26 r
Slide 11: Personalised cancer risk assessment (geneType)
rsonal use only Personalised cancer risk assessment designed to support earlier detection and prevention. www.genetype.com Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY) www.rhythmbio.com
Slide 12: Personalised cancer risk assessment at scale
Personalised cancer risk assessment at scale geneType CANCER RISK ASSESSMENT PLATFORM rsonal use only How geneType reaches the market A broader cancer portfolio Six# cancer risk assessments, including three that complement Rhythm’s protein biomarker programs. Clinics – 25% 25% Direct volume. healthc
Slide 13: Commercial portfolio supported by comprehensive product pipeline
Our current commercial portfolio is supported by a comprehensive product pipeline Seven tests on the market today; a pipeline across nine cancers. rsonal use only COLORECTAL PANCREATIC MELANOMA JO TIENT URNEY PROSTATE CERVICAL OVARIAN A GASTRIC P > BREAST > LUNG MONITORING AND RISK MINIMAL RESIDUAL
Slide 14: FY27 Catalysts
FY27 Catalysts What we delivered in Q1 and what’s coming next. rsonal use only Done ✓ Coming next Q1 FY27 (July – September 2026) Q2 FY27 (OCTOBER – DECEMBER 2026) › ColoSTAT® ordering in Best Practice (Nov 2026) ✓ ColoSTAT® ordering live in MedicalDirector (Aug 2026) › Continued expansion of 4Cyte
Slide 15: Why Rhythm Biosciences? Why now?
Why Rhythm Biosciences? Why now? rsonal use only Dual-platform precision diagnostics strategy Longitudinal disease management: combining personalised risk assessment and earlier cancer detection. Large global addressable markets Exposure to significant and growing global cancer diagnostics demand. C
Slide 16: Team
Team Experienced diagnostics leadership executing the next phase of commercial growth rsonal use only Gary Goh Head of Laboratory David Atkins, PhD Sue MacLeman Carl Stubbings Maureen Baker Operations and RA/QA CEO & MD Interim Non-Executive Non-Executive Director Non-Executive Director Chair Former
Slide 17: Commercial-stage cancer diagnostics platforms entering growth phase
rsonal use only Commercial-stage cancer diagnostics platforms entering a significant growth phase. Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY) www.rhythmbio.com
Slide 18: Thank you!
rsonal use only Thank you! David Atkins, PhD david.atkins@rhythmbio.com www.rhythmbio.com